Amine Functional Polyamides for Biofilm Disruption

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for mucositis, surgical site infections, and chronic lung infections in cystic fibrosis patients, particularly those caused by Pseudomonas aeruginosa, are inadequate in preventing inflammation, infection, and biofilm formation, leading to significant morbidity and mortality.

Innovation Solution

Development of amine functional polyamide compounds that incorporate amine and ammonium groups along the polymer chain, which can be used in pharmaceutical compositions to treat mucositis, surgical site infections, and cystic fibrosis-related lung infections, including those with biofilm formation, by forming coatings for biomedical devices and surfaces to prevent infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional antibacterial therapies are used in CF patients, then bacterial growth may be initially inhibited, but biofilm formation increases tolerance to antibiotics and treatment difficulty

Engineering Contradiction:

Improveantibacterial efficacyVSAvoidbiofilm formation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs polymeric compounds with multiple functional groups (cationic, hydrophobic, and hydrophilic moieties) to create a composite antimicrobial agent that can simultaneously disrupt biofilm matrices and kill bacteria, overcoming the limitation of traditional single-function antibiotics

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The invention changes the physical and chemical parameters of the antimicrobial agent by using polymers with specific molecular weights, charge densities, and amphiphilic characteristics, enabling the compound to penetrate and disrupt biofilms while maintaining antibacterial activity

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If conventional treatments are applied for mucositis and surgical site infections, then some infection control is achieved, but inflammation and ulceration continue to cause morbidity

Engineering Contradiction:

Improveinfection controlVSAvoidinflammation and ulceration

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The polymeric compounds act as intermediaries that simultaneously address multiple pathological processes - they bind to bacterial cell walls, disrupt biofilm matrices, and modulate inflammatory responses, providing a multi-target therapeutic approach

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent describes compounds with universal applicability across different infection types (mucositis, surgical site infections, CF lung infections) and different pathogen types, achieved through the multi-functional nature of the polymeric structure that can interact with diverse biological targets

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP2970586B1Amine functional polyamides

Publication Date: 2022.12.07 GENZYME CORP

Figure 1

AI summary

Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.